(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 May 2015 (21.05.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/073491 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61P 31/16* (2006.01)
A61K 31/497 (2006.01)

(21) International Application Number:
PCT/US2014/065144

(22) International Filing Date:
12 November 2014 (12.11.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/903,840 13 November 2013 (13.11.2013) US

(71) Applicant: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 50 Northern Avenue, Boston, MA 02210 (US).

(72) Inventors: **SIMONE, Eric, Arthur**; 174 Crane Neck Street, West Newbury, MA 01985 (US). **SANGHVI, Tapan**; 157 Summer St., Apt. #2, Watertown, MA 02472 (US). **MAHALINGAM, Alamelu**; 1428 Massachusetts Avenue, Arlington, MA 02476 (US). **STAVROPOULOS, Katherine**; 90 Quincy Shore Dr., Apt #506, Quincy, MA 02171 (US).

(74) Agent: **WEBER, Andrew, N.**; Honigman Miller Schwartz And Cohn LLP, 350 East Michigan Avenue, Suite 300, Kalamazoo, MI 49007-3800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/073491 A1

(54) Title: FORMULATIONS OF AZAINDOLE COMPOUNDS

(57) Abstract: A pharmaceutical composition comprises: a) 5 wt% to 95 wt% of a HC1 salt of Compound (1)·χH20 by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt% to 95 wt% of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HC1 salt of Compound (1)·χH20 and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HC1 salt of Compound (1)·χ¾0 and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.